Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.62 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | AOC3 | Q16853 | 6/20 | 0.52 |
| ▸ | F2 | P00734 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL82461 | 1.00 | DPP4 (0.65) | DPP4KDM4EADRA2AADRA2CLMNA | |
| SCHEMBL2438955 | 1.00 | DPP4 (0.65) | DPP4KDM4EADRA2AADRA2CLMNA | |
| SCHEMBL3802461 | 1.00 | DPP4 (0.65) | DPP4KDM4EADRA2AADRA2CLMNA | |
| SCHEMBL186279 | 1.00 | DPP4 (0.65) | DPP4KDM4EADRA2AADRA2CLMNA | |
| SCHEMBL82462 | 1.00 | DPP4 (0.65) | DPP4KDM4EADRA2AADRA2CLMNA | |
| SCHEMBL17514076 | 1.00 | DPP4 (0.65) | DPP4KDM4EADRA2AADRA2CLMNA | |
| SCHEMBL14959742 | 1.00 | DPP4 (0.65) | DPP4KDM4EADRA2AADRA2CLMNA | |
| SCHEMBL1131702 | 1.00 | DPP4 (0.65) | DPP4KDM4EADRA2AADRA2CLMNA | |
| SCHEMBL8120379 | 0.89 | DPP4 (0.52) | DPP4KDM4EADRA2AADRA2CLMNA | |
| Alcohol SCHEMBL8325116 | 0.89 | KDM4E (0.57) | DPP4KDM4EADRA2AADRA2CLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3694864-B1 | BORONIC ACID DERIVATIVES AND SYNTHESIS THEREOF | QPEX BIOPHARMA INC (US) | 2025-03-05 | — | — | EP | claimed |
| US-11286270-B2 | Boronic acid derivatives and synthesis thereof | QPEX BIOPHARMA, INC. (US) | 2022-03-29 | — | — | US | claimed |
| US-20200407373-A1 | BORONIC ACID DERIVATIVES AND SYNTHESIS THEREOF | QPEX BIOPHARMA, INC. | 2020-12-31 | — | — | US | claimed |
| EP-3694864-B1 | BORONIC ACID DERIVATIVES AND SYNTHESIS THEREOF | QPEX BIOPHARMA INC (US) | 2025-03-05 | — | — | EP | disclosed |
| US-11286270-B2 | Boronic acid derivatives and synthesis thereof | QPEX BIOPHARMA, INC. (US) | 2022-03-29 | — | — | US | disclosed |
| US-20200407373-A1 | BORONIC ACID DERIVATIVES AND SYNTHESIS THEREOF | QPEX BIOPHARMA, INC. | 2020-12-31 | — | — | US | disclosed |
| US-20200407373-A1 | BORONIC ACID DERIVATIVES AND SYNTHESIS THEREOF | QPEX BIOPHARMA, INC. | 2020-12-31 | — | — | US | disclosed |
| EP-3694864-A1 | BORONIC ACID DERIVATIVES AND SYNTHESIS THEREOF | Qpex Biopharma, Inc. (US) | 2020-08-19 | — | — | EP | disclosed |
| WO-2019075084-A1 | BORONIC ACID DERIVATIVES AND SYNTHESIS THEREOF | QPEX BIOPHARMA, INC. (US) | 2019-04-18 | — | — | WO | disclosed |
| US-20170260203-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2017-09-14 | — | — | US | disclosed |
| US-7825264-B2 | Substituted heterocycles, their use as medicament, and pharmaceutical preparations comprising them | SANOFI-AVENTIS (FR) | 2010-11-02 | — | — | US | disclosed |
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-13 | — | — | US | disclosed |
| US-20080188520-A1 | Substituted heterocycles, their use as medicament, and pharmaceutical preparations comprising them | SANOFI-AVENTIS (FR) | 2008-08-07 | — | — | US | disclosed |
| EP-1899320-A1 | SUBSTITUTED PYRR0LIDIN-2-0NES , PIPERIDIN-2-0NES AND ISOTHIAZOLIDINE-1, 1-DIOXIDES, THEIR USE AS KVl .5 POTASSIUM CHANNEL BLOCKERS AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | Sanofi-Aventis (FR) | 2008-03-19 | — | — | EP | disclosed |
| WO-2006136305-A1 | SUBSTITUTED PYRR0LIDIN-2-0NES , PIPERIDIN-2-0NES AND ISOTHIAZOLIDINE-1, 1-DIOXIDES, THEIR USE AS KVl .5 POTASSIUM CHANNEL BLOCKERS AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | SANOFI-AVENTIS (DE) | 2006-12-28 | — | — | WO | disclosed |
| US-5089642-A | Using diphenyl hydroxyl amines coupled to support by amine nitrogen as separation agents | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1992-02-18 | — | — | US | disclosed |
| US-5041573-A | Chromatography separation | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1991-08-20 | — | — | US | disclosed |
| US-4966985-A | Optically active carboalkylated amino alcohols and their utilization in optical resolution | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1990-10-30 | — | — | US | disclosed |
| EP-0231515-B1 | UTILISATION OF OPTICALLY ACTIVE CARBOALKYLATED AMINO ALCOHOLS IN OPTICAL RESOLUTION | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1990-09-26 | — | — | EP | disclosed |
| EP-0231515-A1 | Utilisation of optically active carboalkylated amino alcohols in optical resolution | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 1987-08-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | REN, AGTR1, AGTR2 | DPP4 4179/4885KDM4E 780/4885ADRA2A 66/4885 |
| US-20170260203-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | NR4A1, NCOA4, NR4A2 | DPP4 168/4885KDM4E 257/4885ADRA2A 3971/4885 |
| US-20200407373-A1 | BORONIC ACID DERIVATIVES AND SYNTHESIS THEREOF | BTD, BLVRB, BLK | DPP4 596/4885KDM4E 2136/4885ADRA2A 2852/4885 |
| US-20080188520-A1 | Substituted heterocycles, their use as medicament, and pharmaceutical preparations comprising them | KCNH1, MLLT3, CYP1A2 | DPP4 3580/4885KDM4E 2964/4885ADRA2A 307/4885 |
| US-11286270-B2 | Boronic acid derivatives and synthesis thereof | BTD, BLVRB, BLK | DPP4 596/4885KDM4E 2136/4885ADRA2A 2852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.